Numerion Labs
Renamed from Atomwise, announced Oct 2025.
Data as of .
Company facts
-
Founded
2012
-
Headquarters
United States (San Francisco)
Latest funding round
- Round
- Equity offering (SEC Form D, as Numerion Labs)
- Date
- Mar 19, 2026
- Amount
- $19.8M
Drug discovery partners
3 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
Sanofi Pharma
Exclusive multi-target research collaboration (up to five targets),
$20M upfront ($1B+ total potential)
-
GC Pharma Pharma
Hemophilia small-molecule discovery partnership,
Terms not disclosed
-
Hansoh Pharma
Collaboration,
Terms not disclosed
Big tech ties
Not counted as pharma partners.
-
NVIDIA
Research collaboration (APEX GPU screening paper),
Recent news
-
Form D shows $19.8M sold of a $35M equity offering (company now named Numerion Labs)
-
Rebrands as Numerion Labs; publishes APEX ultra-fast virtual screening work with NVIDIA
-
$44M+ Series C and new CEO
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.